Most Profitable Cancer Fighters Companies

Net Income
Net IncomeEfficiencyMarket RiskExp Return
1REGN Regeneron Pharmaceuticals
4.41 B
(0.06)
 2.03 
(0.11)
2BDX Becton Dickinson and
1.71 B
 0.02 
 1.37 
 0.03 
3ARGX argenx NV ADR
804.13 M
(0.03)
 1.68 
(0.05)
4HALO Halozyme Therapeutics
444.09 M
 0.35 
 1.44 
 0.50 
5HCM HUTCHMED DRC
37.73 M
 0.04 
 3.53 
 0.13 
6CTMX CytomX Therapeutics
31.87 M
(0.17)
 4.67 
(0.78)
7PBYI Puma Biotechnology
30.28 M
 0.06 
 4.82 
 0.29 
8TGTX TG Therapeutics
23.38 M
 0.12 
 3.99 
 0.48 
9RIGL Rigel Pharmaceuticals
17.48 M
 0.09 
 4.42 
 0.39 
10HRTX Heron Therapeuti
(13.58 M)
 0.15 
 5.61 
 0.82 
11NCNA NuCana PLC
(19 M)
(0.16)
 4.89 
(0.76)
12BYSI BeyondSpring
(21.03 M)
(0.01)
 2.84 
(0.02)
13CRVS Corvus Pharmaceuticals
(27.03 M)
(0.08)
 3.71 
(0.30)
14CLLS Cellectis SA
(36.76 M)
(0.01)
 6.34 
(0.06)
15XBIT XBiotech
(38.53 M)
(0.06)
 4.21 
(0.26)
16CRIS Curis Inc
(47.41 M)
(0.02)
 6.25 
(0.15)
17FGEN FibroGen
(47.58 M)
(0.04)
 9.20 
(0.36)
18ANTX AN2 Therapeutics
(64.73 M)
 0.07 
 2.83 
 0.19 
19MGNX MacroGenics
(66.97 M)
(0.20)
 3.86 
(0.79)
20BPMC Blueprint Medicines Corp
(67.09 M)
 0.04 
 3.67 
 0.13 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.